Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.
Gå till den engelska sidan
7-day roundup
The 10 most notable cure or vaccine studies from the last week.
A trial tests a one-time CRISPR gene-edited stem cell therapy for severe sickle cell disease, aiming to stop painful vaso-occlusive crises.
Read lead report →A first-in-human trial tests SGX-001, a gene therapy using a patient's own stem cells, to restore immune function in chronic granulomatous disease.
Read report →A trial tests a one-time gene therapy infusion for Sanfilippo syndrome (MPS IIIB), aiming to restore a missing enzyme and slow the disease's effects.
Read report →A trial tests whether long-acting HIV antibodies plus low-dose nivolumab can help people control HIV without daily antiretroviral therapy.
Read report →A phase II trial tests pCAR-19B, an anti-CD19 CAR-T therapy, in people with CD19-positive relapsed or refractory B-cell acute lymphoblastic leukemia.
Read report →A first-in-human Phase 1 trial tests SRN-101, an experimental therapy given directly into recurrent high-grade glioma tumors before surgery, in a small group of
Read report →A phase 1/2a trial tests whether PRO-1562, an oral drug designed to repair myelin, is safe and can improve vision and nerve signaling in multiple sclerosis.
Read report →The SAFARI trial tests whether daily oral immunotherapy can safely build lasting tolerance to peanut, tree nut, or sesame allergy in children under age 2.
Read report →A 550-person study in India tests whether a 4-month moxifloxacin-based regimen can cure new pulmonary TB as effectively as standard 6-month treatment.
Read report →A Phase 2 trial tests whether oral sildenafil can repair brain damage in newborns who experienced oxygen loss at birth, measuring brain injury and safety.
Read report →Trials whose completion date fell in this window and whose status is actually Completed. Results usually follow later.